BPC-157 focuses on vascular systems, while TB-500 drives cellular and structural systems
10.1016/S0891-5849(99)00177-X
In diabetes, hyperglycemia is the primary factor that produces complexities for a long time, including cardiovascular disease, diabetic neuropathy, retinopathy, immune dysfunction, and pulmonary disorder
No commercial antibody kits for BPC-157 are available, so cross-reactivity is negligible
Key Regulatory Points as of 2026: Not FDA-approved for any medical indication Cannot legally be sold as a drug, food, or dietary supplement for human consumption Legally sold as a "research chemical," not intended for human use Not a DEA-scheduled substance, so possession is not illegal (unlike anabolic steroids) Many medical clinics offer BPC-157 treatments despite lack of approval The FDA has expressed safety concerns due to the lack of human clinical trial data and the potential for adverse effects from unregulated manufacturing
& Vaes, W